AmpliMed Corp.

Chemotherapy developer completes extended series A financing

Published in Health Business Week, June 11th, 2004

AmpliMed Corp. announced that it has successfully raised a total of $9.25MM to complete its Series "A" preferred stock offering. Valley Ventures III LP (Scottsdale/Tucson) led the financing, and other participants included Biotech Insight Management (Pebble Beach, California), InvestBio (New York), Solstice Capital (Tucson/Boston) and Village Ventures (Denver).

"We are delighted that our investors have confirmed their confidence in AmpliMed and its clinical development programs, enabling us to successfully complete our first significant round of financing," noted Robert A. Ashley, chairman, CEO and president of AmpliMed.

"This funding will enable us...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2004-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry